Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Subscribe To Our Newsletter & Stay Updated